诱骗受体3—肿瘤基因治疗的新靶点  

Decoy receptor 3:A novel target for gene therapy of cancer

作　　者：张胜行[1] 兰小鹏[1] 

机构地区：[1]福建医科大学临床学院(南京军区福州总医院)解放军检验医学研究所,福建福州350025

出　　处：《医学研究生学报》2008年第3期309-312,共4页Journal of Medical Postgraduates

基　　金：福建省科技厅国际合作重点项目资助(批准号:2004I012)

摘　　要：诱骗受体3(DcR3)又称肿瘤坏死因子受体(TNFR)6B,也有人称之为TR6,是新近发现的TNFR超家族成员之一。DcR3是一种凋亡抑制蛋白(IAP),能抑制肿瘤细胞凋亡和促进肿瘤细胞免疫逃逸。近年来的研究显示,DcR3在人类正常分化组织中很少表达,却特异性表达于常见的肿瘤组织,它的表达上调可预示肿瘤恶性程度和预后。作为肿瘤分子标记物,体液及组织中DcR3高水平表达能作为肿瘤的辅助诊断和治疗监测。应用新近的分子生物技术可以抑制肿瘤细胞中DcR3的表达,从而诱导肿瘤细胞的凋亡。Decoy receptor 3 （ DcR3 ）, also known as tumor necrosis factor receptor 6B （TNFR6B） or TR6, is a newly discovered member of the tumor necrosis receptor superfamily, an apoptosis-prohibiting protein, which can both inhibit the apoptosis and promote the immunity escape of tumor cells. Recent researches have shown that DcR3 is expressed selectively in most human common tumors but not in normal adult tissue, and its up-regulation may predict the malignancy and prognosis of tumors. As a molecular marker of tumor, the high expression of DcR3 in the body fluid can help tumor detection and therapy monitoring. This novel biological technique can be used to inhibit the expression of the DcR3 gene and induce the apoptosis of tumor cells.

关 键 词：诱骗受体3 基因治疗 

分 类 号：R730.231[医药卫生—肿瘤]